Business Context and Reporting Period
The Beauty Health Company, formerly Vesper Healthcare Acquisition Corp., filed this unaudited Form 10-Q for the quarter ended March 31, 2022. The company operates one reportable segment focused on beauty-health products and aesthetic technologies, led by the HydraFacial platform, including delivery systems, serums and consumables. The May 2021 business combination materially affects comparability with the prior-year period.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $75.4 million | $47.5 million | Up 58.6% |
| Gross profit | $51.9 million | $31.7 million | Up 63.6% |
| Gross margin | 68.9% | 66.8% | Up 210 basis points |
| Operating income (loss) | $(13.0) million | $2.4 million | Declined |
| Net income (loss) | $32.5 million | $(3.3) million | Improved |
| Adjusted EBITDA | $2.2 million | $7.0 million | Down 68.4% |
| Adjusted EBITDA margin | 2.9% | 14.8% | Down 11.9 percentage points |
| Net cash used in operating activities | $(38.5) million | $1.3 million provided | Declined |
Delivery Systems revenue was $41.6 million, up 62.2%, and Consumables revenue was $33.8 million, up 54.4%. The company sold 1,849 Delivery Systems units, including 258 trade-ups. Geographic revenue was $44.6 million in the Americas, $12.9 million in Asia-Pacific and $17.9 million in Europe, the Middle East and Africa.
Operating expenses increased to $64.9 million from $29.4 million, primarily reflecting higher selling and marketing costs, increased headcount, stock-based compensation, public-company costs, legal and recruiting expenses, and spending related to the Syndeo launch. Basic earnings per share were $0.22; diluted loss per share was $(0.13) because the warrant liability gain reduced diluted earnings available to common shareholders.
Cash and cash equivalents were $859.2 million at March 31, 2022, compared with $901.9 million at December 31, 2021. Total assets were $1.20 billion and stockholders’ equity was $341.7 million. Inventories increased to $47.0 million from $35.3 million, and accounts receivable increased to $60.8 million from $46.8 million.
Debt and Liquidity
- The company had $730.97 million of convertible senior notes, net of unamortized issuance costs, representing $750 million principal amount of 1.25% convertible notes due October 2026. The estimated fair value was approximately $680.4 million at quarter-end.
- The $50 million revolving credit facility, maturing December 2026, was undrawn. The facility permits up to an additional $50 million of commitments or term loans subject to conditions and lender commitments.
- Cash used in investing activities was $3.4 million, including $3.1 million of property and equipment expenditures and $0.3 million of capitalized software. Financing activities used $0.8 million.
- Management expected 2022 capital expenditures of up to $20 million and stated that available liquidity was sufficient for anticipated working-capital needs and obligations for at least the next twelve months.
Material Changes Versus the Prior Comparable Period
- Revenue growth reflected stronger markets in the Americas, Europe and Asia-Pacific, the Syndeo launch, increased Delivery System placements and higher recurring Consumables demand.
- Gross margin improved through fixed-cost leverage, cost initiatives and distributor-acquisition benefits, partly offset by higher supply-chain and logistics costs.
- Adjusted profitability weakened despite sales growth. Adjusted EBITDA declined to $2.2 million as selling and marketing, general and administrative, personnel, stock-based compensation and launch-related expenses grew faster than revenue.
- Reported net income was substantially affected by a $52.1 million decrease in the fair value of warrant liabilities. Excluding this and other adjustments, adjusted net loss was $8.5 million compared with $0.1 million in the prior-year period.
- Operating cash flow turned negative, primarily because of inventory investment for Syndeo, higher receivables associated with payment-plan participation and continued investments in personnel and systems.
- Andrew Stanleick became President and Chief Executive Officer on February 7, 2022, replacing interim CEO Brenton L. Saunders, who remained Executive Chairman.
Guidance, Outlook, Commentary and Risks
- Management expects continued long-term growth from beauty-health industry trends, international expansion, new products, digital capabilities and increased Delivery System placements that support higher-margin Consumables revenue.
- Management did not provide explicit revenue or earnings guidance in the filing. It expected adjusted EBITDA margin to improve over the long term but identified near-term pressure from supply-chain constraints, inflation and higher shipping costs.
- The Syndeo digitally connected Delivery System became available in the United States on March 7, 2022, with a rolling international release planned.
- COVID-19 continued to create uneven regional demand, travel restrictions and potential operating disruption. China experienced closures during the quarter.
- The company stopped selling and shipping products to its Russian distributor in March 2022 following the Russia-Ukraine conflict. Geopolitical instability, sanctions, market volatility and supply-chain interruption could adversely affect results.
- Other risks include intense competition, changing regulation including potential FDA requirements, foreign-currency exposure, dependence on international markets, customer and industry consolidation, execution of acquisitions and the company’s ability to service debt.
- Disclosure controls and procedures were not effective as of March 31, 2022 because previously identified material weaknesses in internal control over financial reporting continued, particularly insufficient accounting resources. Management was implementing additional personnel, review procedures and information-technology controls.
- The filing states that no legal proceeding was expected to have a material adverse effect on the company. It also states that the company had no material off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Whether revenue growth and Delivery System placements continue after the Syndeo launch and amid COVID-19, geopolitical and supply-chain disruptions.
- Whether operating expenses normalize sufficiently to restore adjusted EBITDA margin and positive operating cash flow.
- The sustainability of reported earnings after excluding the non-cash $52.1 million warrant-liability fair-value gain and other adjustments.
- Cash conversion, inventory levels, receivables collection and working-capital requirements.
- Convertible-note dilution risk, repayment or conversion terms and compliance with the revolving-credit facility’s financial covenants.
- Progress in remediating the material weaknesses in internal controls.
- Potential effects of inflation, shipping costs, foreign exchange, FDA or other regulatory changes, and the Russia-Ukraine conflict.
- The filing’s contractual-obligations disclosure refers to March 31, 2021 rather than March 31, 2022; investors should verify the current obligations schedule in the filed exhibits or related reports.